Bioinformatically expanded next-generation sequencing analysis optimizes identification of therapeutically relevant MET copy number alterations in >50,000 tumors Journal Article


Authors: Solomon, J. P.; Yang, S. R.; Choudhury, N. J.; Ptashkin, R. N.; Eslamdoost, N.; Falcon, C. J.; Martin, A.; Plodkowski, A.; Wilhelm, C.; Shen, R.; Ladanyi, M.; Berger, M.; Zhang, Y.; Drilon, A.; Arcila, M. E.
Article Title: Bioinformatically expanded next-generation sequencing analysis optimizes identification of therapeutically relevant MET copy number alterations in >50,000 tumors
Abstract: Purpose: Clinical relevance thresholds and laboratory methods are poorly defined for MET amplification, a targetable biomarker across malignancies. Experimental Design: The utility of next-generation sequencing (NGS) in assessing MET copy number alterations was determined in >50,000 solid tumors. Using fluorescence in situ hybridization as reference, we validated and optimized NGS analysis. Results: Incorporating read-depth and focality analyses achieved 91% concordance, 97% sensitivity, and 89% specificity. Tumor heterogeneity, neoplastic cell proportions, and genomic focality affected MET amplification assessment. NGS methodology showed superiority in capturing overall amplification status in heterogeneous tumors and defining amplification focality among other genomic alterations. MET copy gains and amplifications were found in 408 samples across 23 malignancies. Total MET copy number inversely correlated with amplified segment size. High-level/focal amplification was enriched in certain genomic subgroups and associated with targeted therapy response. Conclusions: Leveraging our integrated bioinformatic approach, targeted therapy benefit was observed across diverse MET amplification contexts. © 2022 American Association for Cancer Research.
Keywords: genetics; neoplasm; neoplasms; in situ hybridization, fluorescence; fluorescence in situ hybridization; genomics; dna copy number variations; copy number variation; procedures; high throughput sequencing; high-throughput nucleotide sequencing; humans; human
Journal Title: Clinical Cancer Research
Volume: 28
Issue: 21
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2022-11-01
Start Page: 4649
End Page: 4659
Language: English
DOI: 10.1158/1078-0432.Ccr-22-1321
PUBMED: 36044468
PROVIDER: scopus
PMCID: PMC9633455
DOI/URL:
Notes: Article -- Export Date: 1 December 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ronglai Shen
    204 Shen
  2. Marc Ladanyi
    1326 Ladanyi
  3. Michael Forman Berger
    765 Berger
  4. Maria Eugenia Arcila
    657 Arcila
  5. Alexander Edward Drilon
    632 Drilon
  6. Yanming Zhang
    199 Zhang
  7. Axel Stephen Martin
    19 Martin
  8. Soo Ryum Yang
    75 Yang
  9. Clare Jon Wilhelm
    25 Wilhelm
  10. Christina Jade Falcon
    44 Falcon